Having successfully closed a Series A financing for £28m, NodThera can now begin progressing molecules aimed at reducing chronic inflammation, known to be the root cause of a many diseases such as metabolic disorders, cancer and CNS diseases such as Alzheimer’s disease, the British biotech's chief science officer and acting CEO told Scrip.
"We'll use these funds to bring forward our preclinical drugs to target the inflammasome in inflammatory disease and they should allow us to go to proof of concept and then as far as Phase
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?